Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2013 Apr;27(2):341–353. doi: 10.1016/j.hoc.2012.12.004

FIGURE 1. MSKCC Treatment Schema using CAR-modified T cells for patients with relapsed CLL.

FIGURE 1

Patients with relapsed CLL are eligible for enrollment, leukapheresis, and infusion with CAR-modified T cells after treatment with conditioning chemotherapy.